For adults treating their Stage 3 or 4 classical Hodgkin lymphoma for the first time

THE POWER OF ADCETRIS + AVD CAN

Amina was treated with ADCETRIS plus AVD*

In a clinical study, overall survival^† rate was higher and patients had more time without cancer progression when treated with ADCETRIS plus AVD than patients treated with ABVD

Out of 1334 patients in the clinical study, 664 received ADCETRIS plus AVD and 670 received ABVD
Patients lived longer with ADCETRIS: 41% reduced risk of death for patients who were treated with ADCETRIS plus a chemo called AVD compared to traditional chemo (ABVD)
- About 94% of adults treated with ADCETRIS plus AVD and about 89% of adults treated with ABVD were still alive approximately 6 years after starting study treatment
Patients had more time without cancer progression: 23% reduced risk of cancer growing or spreading, receiving additional anticancer therapy, or death when compared to traditional chemo (ABVD)

^†Overall survival means the length of time that patients remain alive after starting study treatment.
ABVD: A combination of 4 chemotherapies—Adriamycin, bleomycin, vinblastine, and dacarbazine.
AVD: A combination of 3 chemotherapies—Adriamycin, vinblastine, and dacarbazine.

ADCETRIS will not work for everyone. Individual results may vary.

See the main study results

Your first treatment choice matters

ADCETRIS plus AVD is a newer alternative to ABVD chemotherapy for patients treating their Stage 3 or 4 Hodgkin lymphoma for the first time.

The Treatment Decision Guide reviews several aspects of these 2 regimens so you can feel confident discussing options with your doctor.

View Treatment Decision Guide

Classical Hodgkin lymphoma, also called Hodgkin's lymphoma, Hodgkin's disease, or Hodgkin's, is a type of cancer of the blood. It starts when lymphocytes, a type of white blood cell, grow out of control.

People with classical Hodgkin lymphoma have abnormal white blood cells called Reed-Sternberg cells in their lymph nodes. These cells usually have a special protein on their surface called CD30, which is a key marker of Hodgkin's. In fact, CD30 is present in approximately 95% of all cases of Hodgkin lymphoma.

Click here to learn more about how ADCETRIS is designed to attach to CD30 to help fight Hodgkin lymphoma.

Relapsed classical Hodgkin lymphoma

For those who have classical Hodgkin lymphoma that has come back after treatment, see how ADCETRIS helped.

See study results

After stem cell replacement

For those who have classical Hodgkin lymphoma at high risk of coming back or getting worse after a stem cell transplant, see how ADCETRIS helped.

See study results

Why ADCETRIS is different

Learn how effective ADCETRIS was in clinical studies and how it works.

See the results of treatment

How ADCETRIS is given

Learn more about what you can expect before starting ADCETRIS treatment.

Review treatment information

Resources

Find resources, financial assistance information, and ways to connect with others.

See what’s available

*Amina was compensated for her participation in this campaign.